Use of umbilical cord blood to treat individuals having a disease, disorder or condition
First Claim
1. A method of treating an individual comprising administration of a composition comprising cord blood or cord blood-derived stem cells, wherein said administration delivers at least 1×
- 1010 total nucleated cells, or at least 1×
109 stem cells, to an individual in need of said administration.
6 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides methods of using cord blood and cord blood-derived stem cells in high doses to treat various conditions, diseases and disorders. The high-dose cord blood and cord blood-derived stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses. In particular, the cord blood or cord blood-derived stem cells are delivered in high doses, e.g., at least 3 billion nucleated cells per treatment, where treatment may comprise a single or multiple infusions. The invention also provides for the use of cord blood or cord blood-derived stem cells from multiple donors without the need for HLA typing.
199 Citations
28 Claims
-
1. A method of treating an individual comprising administration of a composition comprising cord blood or cord blood-derived stem cells, wherein said administration delivers at least 1×
- 1010 total nucleated cells, or at least 1×
109 stem cells, to an individual in need of said administration. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 11, 13, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 26, 27, 28)
- 1010 total nucleated cells, or at least 1×
-
10. A method of treating myelodysplasia which comprises administering cord blood or cord blood-derived stem cells to a patient in need thereof.
-
12. (canceled)
-
19. (canceled)
-
20. (canceled)
Specification